The FDA has selected seven companies, including Eli Lilly and Regeneron, for its new PreCheck pilot program aimed at accelerating regulatory review of new pharmaceutical manufacturing facilities in the U.S. This program allows the FDA to review facilities while they are still under construction, potentially saving up to 14 months in approval time. The initiative supports the Trump administration's push for increased domestic drug production, focusing on complex biologic and genetic medicines. Participating companies include those making drugs to fill supply gaps or address unmet medical needs, with facilities in states like Indiana, New York, and North Carolina.
Starting July 1, Medicare will cover obesity drugs for eligible seniors through its new Bridge demonstration program, requiring a $50 monthly copay. This marks a major expansion in access to treatments from Novo Nordisk and Eli Lilly, previously unaf...
Eli Lilly's stock rose 7% in a single day, marking its largest gain since early February when it surged 10% after releasing 2025 results. The rise reflects broader gains in the healthcare sector but is notably driven by the company's advancements in ...
Shares of AbbVie, Eli Lilly, and Johnson & Johnson are reaching all-time highs, reflecting renewed investor interest in the biopharmaceutical sector. AbbVie's recent announcement to acquire Apogee Therapeutics boosted its stock by 12%. Analysts attri...
Eli Lilly's shares rose nearly 6% following the European Medicines Agency's CHMP recommendation to approve Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all therapy lines. This approval would allow use regardless ...
GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are driving high demand among employees, but their high costs are causing many large employers to reduce or reconsider coverage. Although oral pills are as expensive as injectables and less effe...
